Nantes, France

Gregoire Couvrat-Desvergnes



Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2021

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Gregoire Couvrat-Desvergnes: Innovator in Immunogenicity Reduction

Introduction

Gregoire Couvrat-Desvergnes is a notable inventor based in Nantes, France. He has made significant contributions to the field of immunology, particularly through his innovative research and patenting activities. His work focuses on developing compositions that reduce immunogenicity, which is crucial for improving therapeutic applications.

Latest Patents

Couvrat-Desvergnes holds a patent for a composition with reduced immunogenicity. This invention relates to a composition comprising polyclonal antibodies directed against human cells. The polyclonal antibodies are devoid of a first antigenic determinant selected from a group that includes N-glycol-neuraminic acid (Neu5Gc) and α-1,3-galactose. This composition has potential applications as a medicament, highlighting its importance in medical treatments.

Career Highlights

He is affiliated with the Institut National de la Santé et de la Recherche Médicale, a prestigious research institution in France. His work at this institution has allowed him to collaborate with other experts in the field, further enhancing the impact of his research.

Collaborations

Couvrat-Desvergnes has worked alongside notable colleagues such as Jean-Paul Soulillou and Magali Giral. These collaborations have contributed to the advancement of research in immunology and the development of innovative therapeutic solutions.

Conclusion

Gregoire Couvrat-Desvergnes is a prominent figure in the field of immunology, with a focus on reducing immunogenicity through his patented compositions. His contributions to medical research and collaboration with esteemed colleagues underscore his commitment to advancing healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…